NCT03409614
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03409614 |
| Title | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Regeneron Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | TUR | SVK | ROU | POL | LTU | ITA | IRL | GRC | FRA | AUT |
CKB BOOST